METHSUXIMIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for METHSUXIMIDE (METHSUXIMIDE).
Succinimide anticonvulsant; reduces low-threshold T-type calcium currents in thalamic neurons, thereby suppressing paroxysmal depolarizations and spike-wave activity associated with absence seizures.
| Metabolism | Metabolized hepatically, primarily via hydroxylation by CYP450 enzymes (CYP3A4, CYP2C9, CYP2C19) to an active metabolite, N-desmethylmethsuximide; <1% excreted unchanged in urine. |
| Excretion | Renal: ~85% (50% as parent drug, 35% as inactive metabolites); Fecal: <5%; Biliary: negligible |
| Half-life | Terminal elimination half-life: 1.5–4.5 hours (mean ~2.5 hours) in adults; shorter in children. Requires multiple daily doses for therapeutic concentration maintenance. |
| Protein binding | Negligible; <5% bound (does not bind significantly to albumin or other plasma proteins). |
| Volume of Distribution | Vd: 0.8–1.2 L/kg (suggests distribution into total body water; no extensive tissue binding). |
| Bioavailability | Oral: ~90% (well absorbed; minimal first-pass metabolism). |
| Onset of Action | Oral: 30–60 minutes (therapeutic effect on absence seizures may take 3–6 days). Intravenous: N/A (not available). |
| Duration of Action | Duration: 6–8 hours; due to short half-life, dosing 3–4 times daily is needed. Steady-state achieved in 2–3 days. |
| Molecular Weight | 215.25 |
Initial: 300 mg orally once daily for first week; increase by 300 mg weekly up to 1.2 g/day in 2-3 divided doses. Maintenance: 600-1200 mg/day in 2-3 divided doses.
| Dosage form | CAPSULE |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (GFR <30 mL/min) with monitoring for toxicity; consider dose reduction. |
| Liver impairment | Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Avoid use. |
| Pediatric use | Initial: 10 mg/kg/day in 2-3 divided doses, increase weekly by 5 mg/kg/day; maximum 30 mg/kg/day or 1.2 g/day, whichever is less. |
| Geriatric use | Initiate at low end of dosing range (300 mg/day) due to age-related reduced renal function; titrate slowly with monitoring for CNS effects. |
| 1st trimester | Associated with increased risk of congenital malformations (e.g., neural tube defects, cleft lip/palate) due to folate antagonism. Avoid use unless no safer alternative; high-dose folic acid recommended. |
| 2nd trimester | Risk of teratogenicity persists; may require dose adjustment due to pregnancy-altered pharmacokinetics. Use only if benefit outweighs risk. |
| 3rd trimester | May cause neonatal bleeding (vitamin K deficiency), respiratory depression, and withdrawal symptoms. Administer vitamin K to mother and neonate; monitor for sedation. |
Clinical note
Comprehensive clinical and safety monograph for METHSUXIMIDE (METHSUXIMIDE).
| Placental transfer | Crosses placenta; fetal serum levels approximate maternal levels (extensive transfer). Associated with teratogenicity. |
| Breastfeeding | Excreted into breast milk in low amounts; infant serum levels are subtherapeutic. Cases of rash, sedation, and thrombocytopenia reported. Use caution; monitor infant for somnolence, poor feeding, or bruising. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to succinimidesPorphyria (may induce acute attacks)
| Precautions | May cause drowsiness, dizziness, or blurred vision; caution in activities requiring mental alertness., Abrupt withdrawal may precipitate status epilepticus., May exacerbate grand mal (tonic-clonic) seizures; use with caution in mixed seizure types., Hematologic effects: Case reports of leukopenia, pancytopenia; monitor CBC periodically., Hepatic effects: Rare reports of hepatotoxicity; monitor LFTs., Rash may indicate serious hypersensitivity (e.g., SJS/TEN); discontinue if rash appears., Renal effects: Monitor renal function in patients with pre-existing impairment., Pregnancy: Pregnancy Category C; may cause fetal harm; consider alternative therapy. |
| Food/Dietary | No significant food interactions reported. However, consistent timing of doses with meals may help reduce gastrointestinal upset. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Associated with increased risk of congenital malformations, including oral clefts, cardiac defects, and neural tube defects. Second and third trimesters: Risk of fetal hydantoin syndrome, intrauterine growth restriction, and neurodevelopmental deficits. Neonatal hemorrhage due to vitamin K deficiency is possible. |
| Fetal Monitoring | Monitor methsuximide serum levels every 2-4 weeks; adjust dose to maintain therapeutic levels. Perform fetal ultrasound for anomalies at 18-20 weeks. Monitor for maternal signs of toxicity (ataxia, nystagmus) and fetal distress via non-stress test starting at 32 weeks. |
| Fertility Effects | May cause decreased libido and sexual dysfunction in males. Limited evidence of reduced fertility in females. No clear impact on ovulation or spermatogenesis. |
| Clinical Pearls | Methsuximide is a succinimide anticonvulsant used primarily for absence seizures. Monitor for hepatotoxicity, blood dyscrasias, and lupus-like syndrome. Therapeutic drug monitoring may be useful; target serum concentration 10-40 mcg/mL. Cross-sensitivity with ethosuximide may occur. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly as seizure frequency may increase. · May cause drowsiness or dizziness; avoid driving until effects are known. · Report signs of infection (fever, sore throat), unusual bleeding or bruising, or skin rash immediately. · Avoid alcohol as it may increase central nervous system depression. · Use effective contraception if of childbearing potential; methsuximide may cause fetal harm. · Do not chew or crush extended-release capsules. |